# Bridgebio Pharma (BBIO): value investors who own it

1 value investor held Bridgebio Pharma in their Q3 2026 13F, led by Polen Capital Management.

## 13F holders

| Manager | Portfolio | Value | Change | Quarters held |
| --- | --- | --- | --- | --- |
| Polen Capital Management | 0.0% | $298k | Trimmed -91% | 5 |

## Directors buying and selling (Form 4, last 12 months)

| Date | Who | Role | Bought or sold | Shares | Value |
| --- | --- | --- | --- | --- | --- |
| 2026-09-17 | Kumar Neil | Chief Executive Officer | Sold | 8721 | $602k |
| 2026-09-17 | Kumar Neil | Chief Executive Officer | Sold | 1279 | $89k |
| 2026-08-19 | Kumar Neil | Chief Executive Officer | Sold | 8100 | $679k |
| 2026-08-19 | Kumar Neil | Chief Executive Officer | Sold | 1800 | $152k |
| 2026-08-19 | Kumar Neil | Chief Executive Officer | Sold | 100 | $9k |
| 2026-08-18 | Kumar Neil | Chief Executive Officer | Sold | 17279 | $1.4m |
| 2026-08-18 | Kumar Neil | Chief Executive Officer | Sold | 14602 | $1.2m |
| 2026-08-18 | Kumar Neil | Chief Executive Officer | Sold | 1900 | $154k |
| 2026-08-18 | Kumar Neil | Chief Executive Officer | Sold | 1199 | $100k |
| 2026-07-30 | Apuli Maricel | Chief Accounting Officer | Sold | 2000 | $160k |

Source: SEC filings, via moatshark (https://www.moatshark.com/s/bbio). Values traded and returns are estimates. Not investment advice. Built 2026-10-21.